Immunology
Behcet's Syndrome
13
Pipeline Programs↗
0
Active Trials↗
10
Companies Involved↗
Behcet's syndrome is an emerging landscape with 13 programs across 10 companies. The most active players are Bristol-Myers Squibb, Iovance Biotherapeutics, Inc., Johnson & Johnson. 3 therapies are approved with 2 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 11
Phase 26
Analysis
Modality Breakdown
13programs
Small molecule646%
Monoclonal antibody538%
Protein / enzyme215%
Modality classified for 100% of 13 pipeline programs.
Analysis
Trial Status
3
clinical trials
Completed1 · 33%
Terminated1 · 33%
Withdrawn1 · 33%
Clinical Trials
Trial Activity
Upadacitinib for Refractory Behcet's Syndrome
Completed·—·Phase 2·NCT07080346·27 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)